By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.

Business Economy Health Technology Hims & Hers’ ugly split with Wegovy maker weighs on the firm’s future July 7, 2025 at 6:00 am Updated July 7, 2025 at 6:00 am By Queenie Wong ...

Through the Hims & Hers platform, people would be able to obtain Wegovy for $599 per month. And it seemed as if it would be the start of a promising long-term partnership.